» Articles » PMID: 36149505

A Nomogram for Predicting Recurrence-free Survival of Intermediate and High-risk Neuroblastoma

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 2022 Sep 23
PMID 36149505
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to confirm the independent risk factors for recurrence-free survival (RFS) in intermediate and high-risk neuroblastoma (NB) patients and set up an effective nomogram model for predicting the recurrence of NB. A total of 212 children with intermediate- and high-risk neuroblastoma, who had ever achieved complete remission (CR) or very good partial remission (VGPR) after standardized treatment in this hospital, were chosen as study objects. After retrospective analysis of the clinical data, Cox regression model was used to explore the factors related to the recurrence of neuroblastoma, to determine the variables to construct the Nomogram. The consistency index would predict the accuracy of this nomogram. RFS rate in 1-year, 3-year, 5-year, and 10-year was 0.811, 0.662, 0.639, and 0.604, respectively. Children with MYCN amplification had a higher neuron-specific enolase (NSE) value (P = 0.031) at the initial diagnosis than MYCN non-amplification. The univariate analysis predicted that increased vanillylmandelic acid (VMA) and NSE value and dehydrogenase (LDH) > 1000 U/L were important adverse factors for the recurrence of NB. Multivariate analysis demonstrated that age at diagnosis, tumor localization, MYCN state, histologic subtype, and tumor capsule were significantly associated with RFS (all P values < 0.05). Nomograms were established for predicting the recurrence of NB according to the Cox regression analysis. Internal verification by the Bootstrap method showed that the prediction of the nomogram's consistency index (C-index) was 0.824 (P = 0.023).   Conclusion: Age at diagnosis, tumor localization, MYCN state, histologic category, and tumor capsule were independent risk factors for the recurrence of NB. The nomogram model could accurately predict the recurrence of children with neuroblastoma. What is Known: • The prognoses of neuroblastoma (NB) could vary greatly due to the high heterogeneity, the 5-year survival rate of low-risk NB exceeded 90%, while the 5-year survival rate of children in the intermediate and high-risk groups was not satisfactory.. What is New: • Increased vanillylmandelic acid (VMA) and neuron-specific enolase (NSE) value, and lactate dehydrogenase (LDH)>1000U/L were important adverse factors for the recurrence of NB. • NSE value was more valuable for predicting NB recurrence.

Citing Articles

Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining I-MIBG SPECT-CT radiomics and clinical factors.

Feng L, Yang X, Wang C, Zhang H, Wang W, Yang J Pediatr Radiol. 2024; 54(5):805-819.

PMID: 38492045 DOI: 10.1007/s00247-024-05901-z.


Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an F-FDG PET/CT-based radiomics nomogram.

Feng L, Yao X, Lu X, Wang C, Wang W, Yang J Abdom Radiol (NY). 2024; 49(3):888-899.

PMID: 38315193 DOI: 10.1007/s00261-023-04181-9.


Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.

Feng L, Kan Y, Wang W, Wang C, Zhang H, Xie P J Cancer Res Clin Oncol. 2023; 149(18):16377-16390.

PMID: 37702807 DOI: 10.1007/s00432-023-05398-3.


A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients.

Chen W, Fang Y, Lin P, Bai J, Fang Y, Zhang B Am J Cancer Res. 2023; 13(6):2254-2268.

PMID: 37424797 PMC: 10326575.


Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.

Li M, Duan X, You D, Liu L Front Med (Lausanne). 2023; 10:1184607.

PMID: 37305122 PMC: 10249662. DOI: 10.3389/fmed.2023.1184607.

References
1.
Tsubota S, Kadomatsu K . Origin and initiation mechanisms of neuroblastoma. Cell Tissue Res. 2018; 372(2):211-221. DOI: 10.1007/s00441-018-2796-z. View

2.
Whittle S, Smith V, Doherty E, Zhao S, McCarty S, Zage P . Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017; 17(4):369-386. DOI: 10.1080/14737140.2017.1285230. View

3.
Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

4.
Swift C, Eklund M, Kraveka J, Alazraki A . Updates in Diagnosis, Management, and Treatment of Neuroblastoma. Radiographics. 2018; 38(2):566-580. DOI: 10.1148/rg.2018170132. View

5.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View